Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has completed a private placement with net proceeds in excess of CDN$4.6 million, after fees and expenses associated with this transaction.
- 0 Comments
- FY2014